Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Apyx Class Action: Levi & Korsinsky Reminds Apyx Medical Corporation Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of August 5, 2022 - APYX

APYX

New York, New York--(Newsfile Corp. - June 17, 2022) - Levi & Korsinsky, LLP notifies investors in Apyx Medical Corporation ("Apyx" or the "Company") (NASDAQ: APYX) of a class action securities lawsuit.

The lawsuit on behalf of Apyx investors has been commenced in the the United States District Court for the Middle District of Florida. Affected investors purchased or otherwise acquired certain Apyx Medical Corporation securities between May 12, 2021 and March 11, 2022. Follow the link below to get more information and be contacted by a member of our team:

https://www.zlk.com/pslra-1/apyx-medical-corporation-loss-submission-form-2?prid=28788&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/128265_886854_logo.jpg



Cannot view this video? Visit:
https://www.youtube.com/watch?v=r5chs8oJWZQ

Apyx Medical Corporation NEWS - APYX NEWS

CASE DETAILS: The filed complaint alleges that defendants made false statements and/or concealed that: (1) a significant number of Apyx's Advanced Energy products were used for off-label indications; (2) such off-label uses led to an increase in the number of medical device reports filed by Apyx reporting serious adverse events; (3) as a result, the Company was reasonably likely to incur regulatory scrutiny; (4) as a result of the foregoing, the Company's financial results would be adversely impacted; and (5) as a result of the foregoing, defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

WHAT THIS MEANS TO SHAREHOLDERS: If you suffered a loss in Apyx during the relevant timeframe, you have until August 5, 2022 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

NO COST TO YOU: If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. Discuss your rights with our legal team without cost or obligation.

PROTECT YOUR FINANCIAL INTERESTS: Complete this brief submission form https://www.zlk.com/pslra-1/apyx-medical-corporation-loss-submission-form-2?prid=28788&wire=5 or call 212-363-7500 to discuss the case.

WHY LEVI & KORSINSKY: Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/128265

Tags: